

Status: Currently Official on 16-Feb-2025  
 Official Date: Official Prior to 2013  
 Document Type: USP Monographs  
 DocId: GUID-D8758D10-0FD1-43AD-8A94-42E10CD4308E\_1\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M58357\\_01\\_01](https://doi.org/10.31003/USPNF_M58357_01_01)  
 DOI Ref: j2zqs

© 2025 USPC  
 Do not distribute

## Ofloxacin Ophthalmic Solution

### DEFINITION

Ofloxacin Ophthalmic Solution is a sterile aqueous solution of Ofloxacin. It contains NLT 90.0% and NMT 110.0% of the labeled amount of ofloxacin ( $C_{18}H_{20}FN_3O_4$ ).

### IDENTIFICATION

- **A. THIN-LAYER CHROMATOGRAPHY**

**Standard stock solution:** 3.0 mg/mL of [USP Ofloxacin RS](#) in a mixture of chloroform and methanol (1:1)

**Standard solution:** 0.3 mg/mL of [USP Ofloxacin RS](#) from *Standard stock solution* prepared as follows. Transfer 5.0 mL of *Standard stock solution* to a 50-mL volumetric flask, add 5 mL of water, and dilute with a mixture of chloroform and methanol (1:1) to volume.

**Sample solution:** 0.3 mg/mL of ofloxacin from a portion of Ophthalmic Solution in a mixture of chloroform and methanol (1:1)

**Application volume:** 2  $\mu$ L

**Developing solvent system:** Chloroform, methanol, and a solution (1 in 30) of ammonium hydroxide (150:75:15). Saturate a paper-lined chromatographic chamber with this mixture.

- **B.** The retention time of the ofloxacin peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

- **PROCEDURE**

**Mobile phase:** Acetonitrile, 0.24% sodium dodecyl sulfate, and glacial acetic acid (400:580:20)

**0.05 N hydrochloric acid:** Add 4.0 mL of hydrochloric acid to 500 mL of water, dilute with water to 1000 mL, and mix.

**System suitability solution:** 0.1 mg/mL of [USP Ofloxacin RS](#) and 2.4 mg/mL of propylparaben in acetonitrile

**Standard solution:** 0.06 mg/mL of [USP Ofloxacin RS](#) in 0.05 N hydrochloric acid

**Sample solution:** 0.06 mg/mL of ofloxacin from Ophthalmic Solution in 0.05 N hydrochloric acid

**Chromatographic system**

(See [Chromatography\\_\(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 294 nm

**Column:** 4.6-mm  $\times$  25-cm; 5- $\mu$ m packing L1

**Column temperature:** 35°

**Flow rate:** 1.5 mL/min

**Injection volume:** 20  $\mu$ L

**System suitability**

**Samples:** System suitability solution and Standard solution

**Suitability requirements**

**Resolution:** NLT 2 between the propylparaben and ofloxacin peaks, System suitability solution

**Tailing factor:** NMT 3, Standard solution

**Relative standard deviation:** NMT 2.0%, Standard solution

**Analysis**

**Samples:** Standard solution and Sample solution

Calculate the percentage of the labeled amount of ofloxacin ( $C_{18}H_{20}FN_3O_4$ ) in the portion of Ophthalmic Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak area of ofloxacin from the *Sample solution*

$r_S$  = peak area of ofloxacin from the *Standard solution*

$C_S$  = concentration of [USP Ofloxacin RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of ofloxacin in the *Sample solution* (mg/mL)

**Acceptance criteria:** 90.0%–110.0%

#### SPECIFIC TESTS

- [STERILITY TESTS \(71\)](#): It meets the requirements when tested as directed for *Membrane Filtration* in the test for *Sterility of the Product to Be Examined*.
- [pH \(791\)](#): 6.0–6.8

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers at controlled room temperature.
- [USP REFERENCE STANDARDS \(11\)](#)

[USP Ofloxacin RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
OFLOXACIN OPHTHALMIC SOLUTION	<a href="#">Documentary Standards Support</a>	SM12020 Small Molecules 1
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM12020 Small Molecules 1

**Chromatographic Database Information:** [Chromatographic Database](#)

#### Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 28(4)

**Current DocID: GUID-D8758D10-0FD1-43AD-8A94-42E10CD4308E\_1\_en-US**

**DOI:** [https://doi.org/10.31003/USPNF\\_M58357\\_01\\_01](https://doi.org/10.31003/USPNF_M58357_01_01)

**DOI ref:** j2zqs